Literature DB >> 6104182

Comparison of three methods of central-nervous-system prophylaxis in childhood acute lymphoblastic leukaemia.

D M Green, A I Freeman, H N Sather, S E Sallan, M E Nesbit, J R Cassady, L F Sinks, D Hammond, E Frei.   

Abstract

A retrospective comparison was made of three methods of central-nervous-system prophylaxis in childhood acute lymphoblastic leukaemia; (1) intrathecal methotrexate only; (2) intermediate-dose methotrexate infusion and intrathecal methotrexate and, (3) 2400 rads cranial irradiation and intrathecal methotrexate. The incidence of primary meningeal relapse was statistically significantly lower in both standard-risk patients (age grear than 24 months and less than or equal to 120 months white-cell count less than 20,000) and increased-risk patients (age less than or equal to 24 months or greater than 120 months and/or white-cell count greater than 20,000) whose central-nervous-system prophylaxis included cranial irradiation. The disease-free and overall survival of irradiated increased-risk patients was significantly better than that of unirradiated increased-risk patients. The disease-free survival of standard-risk patients who received intermediate-dose methotrexate was statistically superior to that of the remaining standard-risk patients. There were no significant differences in overall survival between the three groups of standard-risk patients.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6104182     DOI: 10.1016/s0140-6736(80)92664-1

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  9 in total

Review 1.  Pharmacologic strategies for the treatment of meningeal malignancy.

Authors:  S M Blaney; D G Poplack
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

Review 2.  Paediatrics--Part II.

Authors:  B L Priestley; C J Harrison; M P Gerrard; A Gibson
Journal:  Postgrad Med J       Date:  1993-04       Impact factor: 2.401

Review 3.  Treatment of pediatric acute lymphoblastic leukemia: progress achieved and challenges remaining.

Authors:  Paul S Gaynon
Journal:  Curr Hematol Malig Rep       Date:  2007-07       Impact factor: 3.952

Review 4.  Current pharmacological treatment approaches to central nervous system leukaemia.

Authors:  S M Blaney; F M Balis; D G Poplack
Journal:  Drugs       Date:  1991-05       Impact factor: 9.546

5.  Effects of local irradiation and i.v. methotrexate on brain morphology in rabbits: early changes.

Authors:  R Ludwig; W Calvo; B Kober; W E Brandeis
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

6.  Methotrexate-vindesine association in leukemia: pharmacokinetic study.

Authors:  N Tubiana; N Lena; J Barbet; A M Imbert; C Lejeune; D Maraninchi; D Sainty; G Sebahoun; J A Gastaut; J P Cano
Journal:  Med Oncol Tumor Pharmacother       Date:  1985

Review 7.  Childhood acute lymphocytic leukemia: progress and problems in treatment.

Authors:  W P Bowman
Journal:  Can Med Assoc J       Date:  1981-01-15       Impact factor: 8.262

8.  CNS minimal disease therapy in childhood leukaemia: the place for irradiation.

Authors:  O B Eden
Journal:  Br J Cancer       Date:  1990-07       Impact factor: 7.640

9.  Planning and comparisons in clinical trials.

Authors:  H E Kay
Journal:  Br J Cancer       Date:  1983-02       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.